Beyond the scale: 5 surprising realities of GLP-1 research

Public discussion of GLP-1 medicines often centers on weight loss. Research tells a broader, more complicated story. Investigators are studying outcomes involving the liver, joints, brain, and alcohol use, alongside established questions about glucose regulation and body weight.

These findings are not all equally mature. A promising early trial is different from an approved indication, and an improvement in one outcome does not prove an organ has been restored. Five developments show both the potential and the limits of the field.

1. BMI alone is insufficient, but it has not become obsolete

Body mass index is useful for population-level screening, but it cannot distinguish muscle from fat or show exactly where fat is distributed. Two people with the same BMI can have different health risks and levels of physical function.

The professional organization AACE's 2025 algorithm emphasizes adiposity-based chronic disease, or ABCD, and complications when planning care. The approach considers body measurements alongside the health effects associated with excess or dysfunctional fat.

It is therefore more accurate to say BMI alone is not enough than to say BMI is out. Screening measures remain relevant, while complications, fat distribution, symptoms, and individual circumstances help guide decisions.

Population-specific risk thresholds can matter, including for people of Asian ancestry. However, no single ethnic cutoff should be presented as a universal rule across all countries, organizations, or people. The appropriate framework is determined by qualified professionals using locally relevant guidance.

Prescriptions are selected according to approved uses, evidence, contraindications, and the person's needs. A percentage of weight loss does not automatically determine that a particular complication will reverse.

2. Alcohol-use research is promising, not proof of a new approved use

GLP-1 signaling is involved in appetite and is also being studied in reward-related processes. This has led researchers to investigate whether semaglutide might affect alcohol consumption.

A 2026 randomized, placebo-controlled trial in The Lancet enrolled 108 adults with both obesity and alcohol use disorder. Participants received semaglutide or placebo for 26 weeks, with cognitive behavioral support offered to both groups.

Reported reductions in the percentage of heavy-drinking days were 41.1 percentage points in the semaglutide group and 26.4 percentage points in the placebo group. Percentage-point changes should not be confused with relative percentage reductions.

Total alcohol consumption also declined in both groups, with a larger reduction in the semaglutide group. The treatment difference was approximately 467.5 grams of alcohol per 30 days. These are group-level findings from a small, single-center study, not a prediction for an individual.

An earlier 2025 trial in JAMA Psychiatry studied 48 participants over nine weeks at lower doses. The two trials should not be combined into one study or described as definitive evidence for routine use.

Neither trial establishes semaglutide as an approved treatment for alcohol use disorder. A correlation between weight change and drinking change also does not prove a shared brain mechanism. People concerned about alcohol use should seek qualified support rather than self-prescribing. Abruptly stopping heavy alcohol use can be dangerous without appropriate care.

3. Liver and knee findings are meaningful, but do not establish organ regeneration

Liver disease: biopsy-based improvements in MASH

Metabolic dysfunction-associated steatohepatitis, or MASH, involves liver fat, inflammation, and injury that can progress to fibrosis. In the ESSENCE trial's 72-week analysis, 800 adults had biopsy-confirmed MASH and moderate-to-advanced fibrosis without cirrhosis.

The US FDA summary reports that approximately 63% of semaglutide-treated participants achieved MASH resolution without worsening fibrosis, compared with 34% receiving placebo. Fibrosis improvement without worsening MASH occurred in 37% versus 22%.

72-week biopsy outcome	Semaglutide	Placebo
MASH resolution without worsening fibrosis	63%	34%
Fibrosis improvement without worsening MASH	37%	22%

These findings supported a US accelerated approval for an eligible MASH population. The study continues to evaluate longer-term outcomes. Accelerated approval based on biopsy findings is not proof of complete liver restoration or guaranteed prevention of liver failure.

Knee osteoarthritis: pain and function, not proven cartilage repair

The STEP 9 trial enrolled 407 adults with obesity and knee osteoarthritis. At 68 weeks, the average WOMAC pain score decreased by 41.7 points with semaglutide and 27.5 points with placebo. Physical-function scores also improved more in the semaglutide group.

The trial supports improvements in pain, weight, and reported function in the studied population. It did not demonstrate cartilage regrowth or structural joint repair. Weight reduction may reduce loading on the knee, but the study does not by itself prove a specific anti-inflammatory mechanism caused the benefit.

4. Alzheimer's trials show why benefits cannot be assumed across diseases

Encouraging laboratory findings led researchers to test oral semaglutide in early Alzheimer's disease. The phase 3 EVOKE and EVOKE+ trials enrolled a combined 3,808 participants and evaluated outcomes over 104 weeks.

Semaglutide did not significantly improve the primary measure of disease progression compared with placebo. Improvements in some inflammatory markers did not translate into a demonstrated slowing of cognitive decline.

This is a useful reminder that a biological mechanism is not enough to establish a treatment benefit. Results from animal models, changes in blood markers, and outcomes that matter to people can differ.

The trials do not prove a complete explanation for why the approach failed, and they do not settle every question about other medicines or other stages of disease. They do establish that the tested semaglutide regimen did not deliver the hoped-for benefit on the primary endpoint.

5. US compounding rules are changing, but the details matter

This section concerns US FDA policy. It does not describe Indian law, local approvals, or prescription availability in India. Readers in India should seek locally qualified advice and obtain prescriptions through regulated local channels.

The US FDA declared the semaglutide injection shortage resolved on February 21, 2025. Shortage-related enforcement discretion ended on April 22, 2025, for section 503A compounders and May 22, 2025, for section 503B outsourcing facilities, as described in FDA policy.

Those deadlines do not mean all patient-specific compounding became unlawful. Compounding remains subject to statutory conditions, including limits on products that are essentially copies of available approved drugs and requirements relating to individual patient need.

On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. A proposed rule is not the same as a final rule, and policy status should be checked directly with the regulator.

Compounded products are not FDA-approved generic versions of Ozempic or Wegovy. Product quality, dosing, and labeling matter. Discuss the lawful and appropriate options with a prescriber and pharmacist rather than choosing a product based on a social-media label or a low price.

The future of GLP-1 research: promising, with clear boundaries

GLP-1 research extends beyond the scale, but its implications depend on the disease, population, dose, study design, and outcome being measured. Some findings have informed approved uses; others remain preliminary or have not shown the anticipated benefit.

The most useful approach is to ask three questions: What was actually measured? Who was studied? Is this an established option in my country, or an experimental finding? Those distinctions help turn an exciting headline into a more informed conversation with a qualified professional.

Important reader note

This article is for general education, not personalized advice, diagnosis, or treatment. Research findings describe study populations and do not guarantee individual outcomes. Speak with a qualified health professional before changing prescriptions, taking supplements, or starting strenuous exercise, especially if you have a health condition.